Sixtyfour CEO Saarth Shah explains how his company built AI research agents around rigorous evaluation systems rather than language model fluency, creating verification infrastructure that proves ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results